Australia’s active vaccine safety system

 

AusVaxSafety has been actively monitoring the short-term adverse event profile of COVID-19 vaccines used in Australia through post-vaccination safety surveys that allow vaccine recipients to report any adverse events they may have experienced at different intervals following vaccination. These surveys also allow individuals to report pre-existing medical conditions, allowing AusVaxSafety to capture COVID-19 vaccine safety data, specific to Australia, for people affected by cancer and transplant recipients.

AusVaxSafety captures COVID-19 vaccine safety data for the following cancer and transplant recipient population groups:

  • cancer (not including blood or bone marrow cancer) diagnosed in the last 12 months
  • blood cancer (e.g. leukaemia, lymphoma or myelodysplastic syndrome) diagnosed within the last 5 years
  • organ transplant recipients on immune suppressive therapy or bone marrow transplant recipients in the last 2 years

AusVaxSafety has analysed the data collected from people who reported the above pre-existing conditions and have created infographics outlining the short-term adverse event profile for each group, including a comparison to the general population. These infographics provide individuals affected by cancer and transplant recipients with real-world information on what to expect following Pfizer COVID-19 vaccination and can be used when planning for COVID-19 vaccination.

Have you been diagnosed with myocarditis following COVID-19 vaccination?

Enrol in the AusVaxSafety long-term follow-up program to help Australia better understand the long-term effects of myocarditis following COVID-19 vaccination.

Click here to enrol or learn more